Tumour Models London returns in its 6th year and takes a reinvigorated approach towards closing the translational gap between predictable preclinical validation and successful clinical development. Learn how industry leaders are harnessing next generation in vitro and in vivo techniques to better predict efficacy and toxicity into the clinic; and fast track suitable drug candidates by effectively and accurately mimicking the tumour microenvironment. URLs: Brochure: https://go.evvnt.com/143729-0 Booking: https://go.evvnt.com/143729-2 Time: 09:00 to 17:00 Price: Academic: GBP 1199, Drug Developers (Pharma and Biotech): GBP 2199, Vendor: GBP 2799 Speakers: Frank Schnieders, CEO, Provecs Medical | Michael Rugaard Jensen, Head of Drug Discovery Pharmacology, Novartis | Dr. Vinagolu Rajasekhar, Senior Research Scientist, Memorial Sloan Kettering Cancer Center | Daniel Hynes, Preclinical Manager, E-therapeutics |